NIFT 2025 Exam Schedule: Stage 2 Dates Announced for Fashion Technology Entrance Exam
ByAinvest
Sunday, May 18, 2025 3:11 am ET1min read
AVIR--
The virtual investor event scheduled for May 14, 2025, at 10:00 AM ET, will feature key opinion leaders discussing the study outcomes and market opportunities. Atea's Phase 3 program includes trials in North America and globally, aiming to assess the new treatment against existing therapies. Additionally, the company has initiated a $25 million share repurchase program, reflecting a commitment to return capital to shareholders [1].
Financial results for the first quarter of 2025 indicated a net loss of $34.3 million, although this was an improvement from the previous year's loss. The company is also reviewing strategic alternatives, including potential mergers or sales, and has reduced its workforce by approximately 25% [1].
References:
[1] https://www.nasdaq.com/articles/atea-pharmaceuticals-advances-hcv-treatment-ongoing-phase-3-c-beyond-trial-and-promising
The National Testing Agency (NTA) has announced the dates for the Stage 2 examinations of the National Institute of Fashion Technology Entrance Examination (NIFTEE) 2025. The exams will take place on June 8, 2025, and interviews for postgraduate candidates will start on May 26, 2025. The exams will be conducted in Hindi and English through Computer-Based Test (CBT) or Paper-Based Test (PBT) modes, depending on the programme. Admit cards for Stage 2 will be available on the official NIFTEE 2025 portal.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) has reported significant progress in its clinical development efforts for the treatment of hepatitis C virus (HCV). The company announced ongoing enrollment in its Phase 3 C-BEYOND trial, which evaluates the combination of bemnifosbuvir and ruzasvir for HCV treatment. Positive Phase 2 results, presented at the European Association for the Study of the Liver (EASL) Congress 2025, demonstrated high efficacy and safety of the regimen [1].The virtual investor event scheduled for May 14, 2025, at 10:00 AM ET, will feature key opinion leaders discussing the study outcomes and market opportunities. Atea's Phase 3 program includes trials in North America and globally, aiming to assess the new treatment against existing therapies. Additionally, the company has initiated a $25 million share repurchase program, reflecting a commitment to return capital to shareholders [1].
Financial results for the first quarter of 2025 indicated a net loss of $34.3 million, although this was an improvement from the previous year's loss. The company is also reviewing strategic alternatives, including potential mergers or sales, and has reduced its workforce by approximately 25% [1].
References:
[1] https://www.nasdaq.com/articles/atea-pharmaceuticals-advances-hcv-treatment-ongoing-phase-3-c-beyond-trial-and-promising
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet